XM tidak memberikan layanan kepada penduduk Amerika Serikat.
R
R

Roche


Berita

Swiss trade surplus at CHF 4.578 bln in August

TABLE-Swiss trade surplus at CHF 4.578 bln in August Sept 19 (Reuters) - Switzerland ran a merchandise trade surplus of 4.578 billion Swiss francs in August, the Federal Customs Office said on Thursday. KEY FIGURES (millions of Swiss francs) August 2024 July 2024 Imports 15.912 19.215 Exports 20.491 24.092 Balance 4.578 4.877 The figures exclude precious metals and stones, works of art and antiques.
C
L
N
R
R
S

Swiss stocks - Factors to watch on September 19

Swiss stocks - Factors to watch on September 19 ZURICH/GDANSK, September 19 (Reuters) - Here are some of the main factors that may affect Swiss stocks on Thursday: ROCHE HOLDING AG ROG.S Roche says phase III results show Xofluza significantly reduces the transmission of influenza viruses. RICHEMONT CFR.S - 2.75 CHF/shr dividend ECONOMY Swiss August trade balance due at 0600 GMT.
A
R
R
S

Roche Says Phase III Results Show Xofluza Significantly Reduces The Transmission Of Influenza Viruses

BRIEF-Roche Says Phase III Results Show Xofluza Significantly Reduces The Transmission Of Influenza Viruses Sept 19 (Reuters) - ROCHE HOLDING AG ROG.S : POSITIVE PHASE III RESULTS SHOW XOFLUZA SIGNIFICANTLY REDUCES THE TRANSMISSION OF INFLUENZA VIRUSES DATA FROM CENTERSTONE STUDY SHOWS SINGLE-DOSE XOFLUZA REDUCES TRANSMISSION OF INFLUENZA FROM AN I
R

Vontobel assesses obesity drugs impact for Swiss insurers, med-tech companies

BUZZ-Vontobel assesses obesity drugs impact for Swiss insurers, med-tech companies ** Vontobel estimates the market potential for obesity drugs in the U.S. to reach a three-digit billion U.S. dollar amount and picks Swiss Re SRENH.S and Ypsomed YPSN.S as the most likely to profit from it ** Among Swiss life insurers, Swiss Re could benefit the most from a rising demand in life and health reinsurance, with a market share of about 15%, as obesity drugs improve life expectancy, it says ** Its posit
B
H
N
R
S
S
Z

Roche Says FDA Approves Ocrevus Zunovo™

BRIEF-Roche Says FDA Approves Ocrevus Zunovo™ Sept 16 (Reuters) - ROCHE HOLDING AG ROG.S : FDA APPROVES OCREVUS ZUNOVO™ AS THE FIRST AND ONLY TWICE-A-YEAR 10-MINUTE SUBCUTANEOUS INJECTION FOR PEOPLE WITH RELAPSING AND PROGRESSIVE MULTIPLE SCLEROSIS THIS APPROVAL IS BACKED BY A DECADE OF PROVEN SAFETY AND EFFICACY DATA OF OCREVUS® IV, WITH OVER
R

US FDA approves injectable version of Roche's multiple sclerosis therapy

UPDATE 1-US FDA approves injectable version of Roche's multiple sclerosis therapy Adds price and availability in paragraph 4 Sept 13 (Reuters) - The U.S. Food and Drug Administration on Friday approved Roche's ROG.S under-the-skin injection to treat patients with multiple sclerosis. The subcutaneous or under-the-skin therapy called Ocrevus Zunovo has the potential to expand treatment options to centers unable to administer the IV version.
B
N
R

US FDA approves injectable version of Roche's multiple sclerosis therapy

US FDA approves injectable version of Roche's multiple sclerosis therapy Sept 13 (Reuters) - The U.S. Food and Drug Administration on Friday approved Roche's ROG.S under-the-skin injection to treat patients with multiple sclerosis. The subcutaneous or under-the-skin therapy called Ocrevus Zunovo has the potential to expand treatment options to centers unable to administer the IV version.
B
N
R

FDA Approves Ocrevus Zunovo For People With Relapsing And Progressive Multiple Sclerosis

BRIEF-FDA Approves Ocrevus Zunovo For People With Relapsing And Progressive Multiple Sclerosis Sept 13 (Reuters) - Genentech: FDA APPROVES OCREVUS ZUNOVO™ AS THE FIRST AND ONLY TWICE-A-YEAR 10-MINUTE SUBCUTANEOUS INJECTION FOR PEOPLE WITH RELAPSING AND PROGRESSIVE MULTIPLE SCLEROSIS Source text for Eikon: ID:nBw29jVlta
R

Top of the Street: Roche, Fresenius, BASF, AstraZeneca, Rational, PSP Swiss Property, Swiss Prime Site

BUZZ-Top of the Street: Roche, Fresenius, BASF, AstraZeneca, Rational, PSP Swiss Property, Swiss Prime Site A round-up of notable broker activity this morning from Europe's top-ranked* analysts: ** Deutsche Bank cuts Roche ROG.S to "sell" from "buy", citing limited catalyst due to a risk of Roche creating a lot of sunk cost for little ultimate return ** J.P.Morgan upgrades Fresenius FREG.DE to "overweight" from "neutral" as it sees earnings compression at the German healthcare group coming to an
A
B
F
J
R
R
S
P
F

FDA Approves Roche’s Tecentriq Hybreza

BRIEF-FDA Approves Roche’s Tecentriq Hybreza Sept 13 (Reuters) - ROCHE HOLDING AG ROG.S : FDA APPROVES ROCHE’S TECENTRIQ HYBREZA, THE FIRST AND ONLY SUBCUTANEOUS ANTI-PD-(L)1 CANCER IMMUNOTHERAPY TECENTRIQ HYBREZA PROVIDES PATIENTS AND PHYSICIANS WITH GREATER FLEXIBILITY OF TREATMENT OPTIONS WHILE SHOWING SAFETY AND EFFICACY CONSISTENT WITH INT
R

US FDA approves injectable version of Roche's multiple sclerosis therapy

UPDATE 1-US FDA approves injectable version of Roche's multiple sclerosis therapy Adds background throughout Sept 12 (Reuters) - The U.S. Food and Drug Administration on Thursday approved Roche's ROG.S under-the-skin injection to treat patients with multiple sclerosis. The therapy is already approved as an infusion or IV therapy for multiple sclerosis, which is given twice a year, under the brand name Ocrevus.
B
N
R

US FDA approves injectable version of Roche's multiple sclerosis therapy

UPDATE 1-US FDA approves injectable version of Roche's multiple sclerosis therapy Adds background throughout Sept 12 (Reuters) - The U.S. Food and Drug Administration on Thursday approved Roche's ROG.S under-the-skin injection to treat patients with multiple sclerosis. The therapy is already approved as an infusion or IV therapy for multiple sclerosis, which is given twice a year, under the brand name Ocrevus.
B
N
R

US FDA approves injectable version of Roche's multiple sclerosis therapy

US FDA approves injectable version of Roche's multiple sclerosis therapy Sept 12 (Reuters) - The U.S. Food and Drug Administration on Thursday approved Roche's ROG.S under-the-skin injection to treat patients with multiple sclerosis. Reporting by Urvi Dugar; Editing by Subhranshu Sahu
R

FDA Approves Genentech’S Tecentriq Hybreza, The First And Only Subcutaneous Anti-Pd-(L)1 Cancer Immunotherapy

BRIEF-FDA Approves Genentech’S Tecentriq Hybreza, The First And Only Subcutaneous Anti-Pd-(L)1 Cancer Immunotherapy Sept 12 (Reuters) - Roche Holding AG ROG.S : FDA APPROVES GENENTECH’S TECENTRIQ HYBREZA, THE FIRST AND ONLY SUBCUTANEOUS ANTI-PD-(L)1 CANCER IMMUNOTHERAPY ROCHE HOLDING AG - FDA APPROVES GENENTECH'S TECENTRIQ HYBREZA FOR SUBCUTANE
R

FDA Approves atezolizumab And hyaluronidase-tqjs For Subcutaneous Injection

BRIEF-FDA Approves atezolizumab And hyaluronidase-tqjs For Subcutaneous Injection Sept 12 (Reuters) - FDA: FDA APPROVES ATEZOLIZUMAB AND HYALURONIDASE-TQJS FOR SUBCUTANEOUS INJECTION
R

Roche shares knocked by concern over side effects in obesity pill trial

UPDATE 1-Roche shares knocked by concern over side effects in obesity pill trial Roche shares fall 3.5% Early study trial showed high rate of temporary side effects JP Morgan analysts say heart rate increase is as a concern Roche plans slower ramp-up of pill dose in next trial Updates share price in paragraph 2, further details on side effects in pill trial in paragraphs 6 and 8 FRANKFURT, Sept 12 (Reuters) - Shares in Roche ROG.S dropped to a two-month low on Thursday after an experimental weig
J
P
R

Roche shares drop on side effects result in early-stage obesity pill trial

Roche shares drop on side effects result in early-stage obesity pill trial FRANKFURT, Sept 12 (Reuters) - Shares in Roche ROG.S fell on Thursday after an early-stage obesity pill candidate that carries high market hopes was linked to a high rate of temporary side effects in its initial test phase on humans. Roche shares were down 4% at the open at 0700 GMT after the company presented late on Wednesday details on the trial .
P
R

Roche slides on side effects concerns for its weigh-loss pill

BUZZ-Roche slides on side effects concerns for its weigh-loss pill ** Shares in Roche ROG.S drop around 4%, with analysts pointing to concerns around side effects of its experimental weight-loss pill, CT-996 ** J.P.Morgan says in a note that the CT-996 tolerability data raises questions on overall product profile, with high rates of side effects th
R

Swiss stocks - Factors to watch on September 12

Swiss stocks - Factors to watch on September 12 ZURICH/GDANSK, Sep 12(Reuters) - Here are some of the main factors that may affect Swiss stocks on Thursday: Roche ROG.S Roche said on Wednesday the promising results of an early-stage trial of its experimental weight-loss pill that bolstered its shares in July were based on just six patients, underscoring the uncertainty of the development project.
B
R
S

Roche says early-stage obesity pill results were based on just six patients

UPDATE 1-Roche says early-stage obesity pill results were based on just six patients Adds detail of trial in paragraph 6, company comment in paragraph 7, further detail in paragraphs 8-10 FRANKFURT, Sept 11 (Reuters) - Roche ROG.S said on Wednesday the promising results of an early-stage trial of its experimental weight-loss pill that bolstered its shares in July were based on just six patients, underscoring the uncertainty of the development project.
P
R



Kondisi

Aset Populer

Pengungkapan: Entitas XM Group menyediakan layanan khusus eksekusi dan akses ke Fasilitas Trading Online kami, yang memungkinkan Anda untuk melihat dan/atau menggunakan konten yang tersedia pada atau melalui situs, yang tidak untuk mengubah atau memperluas, serta tidak mengubah atau memperluas hal tersebut. Akses dan penggunaan ini selalu sesuai dengan: (i) Syarat dan Ketentuan; (ii) Peringatan Risiko; dan (iii) Pengungkapan Penuh. Oleh karena itu, konten disediakan hanya sebagai informasi umum. Anda juga harus ketahui bahwa konten Fasilitas Trading Online kami bukan sebagai ajakan atau tawaran untuk untuk melakukan transaksi apa pun di pasar finansial. Trading di pasar finansial mana pun melibatkan tingkat risiko yang signifikan pada modal Anda.

Semua materi yang diterbitkan di Fasilitas Trading Online kami hanya untuk tujuan edukasi/informasi dan tidak boleh mengandung nasihat dan rekomendasi finansial, pajak investasi atau trading, catatan harga trading kami, penawaran, permintaan, transaksi dalam instrumen finansial apa pun atau promo finansial untuk Anda yang tidak diminta.

Konten pihak ketiga apa pun, serta konten yang disiapkan oleh XM, seperti opini, berita, riset, analisis, harga, informasi lain atau link ke situs pihak ketiga yang tersedia "sebagaimana adanya", sebagai komentar pasar umum dan bukan menjadi nasihat investasi. Sejauh konten apa pun ditafsirkan sebagai penelitian investasi, Anda harus memperhatikan dan menerima bahwa konten tersebut tidak dimaksudkan dan belum disiapkan sesuai dengan persyaratan hukum yang dirancang untuk mempromosikan kemandirian riset investasi dan dengan demikian akan dianggap sebagai komunikasi pemasaran di bawah hukum dan peraturan yang relevan. Mohon dipastikan bahwa Anda telah membaca dan memahami Notifikasi pada Riset Investasi Non-Independen dan Peringatan Risiko kami mengenai informasi di atas, yang dapat diakses disini.

Peringatan Resiko: Modal Anda beresiko. Produk dengan leverage mungkin tidak cocok bagi semua orang. Silahkan pertimbangkan Pengungkapan Resiko kami.